Buried in the five peptide-vendor warning letters the FDA posted on September 1 is a line that has nothing to do with peptides. In the letter to Peak Performance Peptides, the agency's enumerated list of unapproved drugs has six entries, and the first one is "Bac water." Not retatrutide, not semaglutide — the diluent.
That is a meaningful escalation, and it is the part of the September batch that almost no coverage picked up. Our breakdown of who received the letters and what compounds were named covered the vendor side. This is the other half: the FDA has spent 2026 building an argument that bacteriostatic water sold in a peptide catalogue is itself a drug, and that argument is now load-bearing across at least six letters.
What the letters actually say
The reasoning is consistent enough across letters to read as boilerplate, which is usually the sign of a settled internal position rather than one reviewer's improvisation.
From the March 31, 2026 letter to Gram Peptides:
Your firm offers "Bacteriostatic Water for Injection" for sale alongside peptide products, which are drugs intended for injection and require reconstitution... The sale of these products together demonstrates that you intend for your "Bacteriostatic Water for Injection" to be used in combination for injection. Therefore, your "Bacteriostatic Water for Injection" is a drug.
From the August 24 letter to Royal Peptides, the agency adds the surrounding material to the argument:
you market bacteriostatic water alongside a "peptide guide" and a "peptide calculator," resources that collectively provide the means to prepare an injectable drug for human administration.
And from the letter to Peptide Partners, which sells the same thing under a house name:
you market bacteriostatic water as a solvent for reconstituting your products, thus, providing the means to prepare an injectable drug for human administration.
Three different sellers, three different product names — "Bacteriostatic Water for Injection," "Bac water," "Reconstitution Solution (BAC)" — and the same conclusion in each. Renaming it did not help. Neither did the research-use-only disclaimer, which the agency dismisses in the same paragraph in every letter: evidence obtained from the website establishes intent regardless of what the label says.
The stated reason the diluent matters at all is the route of administration. The Peak Performance letter puts it directly: injectable products "are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body's key defenses against toxins and microorganisms." Under that framing, the water is not an accessory sold beside the product. It is the last step of the product.
What this does not mean
It is worth being precise here, because the shorthand version circulating on forums — "the FDA banned bac water" — is wrong in a way that matters.
Bacteriostatic Water for Injection, USP is an approved drug product. It has its own DailyMed label, a defined USP specification — sterile, non-pyrogenic water with 0.9% benzyl alcohol as a bacteriostatic preservative, pH 5.7 in a range of 4.5 to 7.0 — and a stated indication for diluting or dissolving drugs for injection. It is manufactured by Hospira and others. None of that changed in 2026.
What the letters establish is narrower: a particular seller's bacteriostatic water becomes an unapproved new drug when that seller's own catalogue and marketing establish that it is intended to reconstitute unapproved peptides for human injection. The legal defect is the intended use the seller created, not the molecule. A pharmacy that dispenses the Hospira product against a prescription is in a completely different position from a peptide site that bundles a diluent with a dosing calculator.
And no letter in either batch is addressed to a buyer. These are correspondence with sellers, asking for a written response within 15 business days. Purchasing a sterile diluent was not addressed, restricted, or made unlawful by any of them.
What actually changed for sourcing
The practical consequence arrived earlier and from a different direction: the mainstream marketplace channel closed.
Amazon's third-party bacteriostatic water listings thinned out sharply across 2025 and into 2026, with sellers describing suspension notices rather than a public category announcement. The mechanics are not mysterious. The USP product carries an Rx-only designation on its FDA label, and Amazon's restricted products policy bars third-party sellers from listing prescription items without documentation that most of those sellers never held. Once compliance teams applied the prescription rule to the category, a listing base built largely on unbranded relabelled stock had no defence. Amazon never explained it, and the absence of an announcement is why the question "why did Amazon remove bacteriostatic water" still generates search volume months later.
That leaves three routes, and they are not equivalent:
- Pharmaceutical distributors. The Hospira/Pfizer USP product through medical supply channels. Highest confidence in specification, with the Rx-only designation governing how it is dispensed.
- Dedicated diluent suppliers. Sellers whose entire catalogue is sterile water rather than peptides — a materially different regulatory posture from the sites in these letters, since there is no peptide catalogue for a "combined intended use" argument to attach to.
- Peptide-vendor bac water. Convenient, and the category the letters are about. Worth knowing that this is the exact bundling the FDA has now named six times.
Our bacteriostatic water sourcing guide walks the specification checks — benzyl alcohol concentration, container type, published manufacturer — that separate genuine USP-spec stock from the relabelled product that filled marketplace listings before the delistings. The failure modes documented in why a reconstituted vial turns cloudy are almost all diluent-quality failures rather than peptide failures.
